Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

corporate strategy

Novartis building

Novartis’ Jakavi turned down by NICE for blood cancer

UK cost-effectiveness watchdog concerned about 'uncertainties' in data in draft guidance

- PMLiVE

EC to investigate Novartis and J&J in antitrust probe

Claims companies agreed to delay entry of generic painkiller

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

NICE backs two cystic fibrosis treatments for NHS use

Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price

Novartis building

Novartis expects tough 2013 before a return to growth

Says it will take a year for new medicine sales to overcome Diovan patent loss

Novartis day

Novartis gets EU approval for Bexsero meningitis B shot

Offers protection for all ages above two months

- PMLiVE

Novartis’ eye drug Jetrea recommended for EU approval

Set to become first drug treatment for sight-threatening condition vitreomacular traction and macular hole

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

Novartis building

Novartis’ Exjade gets EU approval for thalassaemia

First oral treatment for condition characterised by red blood cell problems and anaemia

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

Novartis calls for improvements to UK clinical trial system

Says cost of running studies in the country undermines its attractiveness

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links